Mobile

An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004275-11

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To measure the blood concentrations of pimecrolimus after single and repeated doses of Elidel (pimecrolimus) Cream 1% when applied twice daily for 3 weeks on the whole lesional skin in patients with moderate or severe seborrheic dermatitis (SD).

Critère d'inclusion

  • Seborrheic dermatitis

Liens